Psynomics Announces Gene Tests for Psychiatric Bipolar Disorder
News Feb 05, 2008
Psynomics, Inc. has announced that two tests for bipolar disorder are available for purchase on its web-site, along with descriptions, references and instructions. Either patients or their physicians may order the simple, non-invasive kits to collect DNA samples from saliva and the results are reported confidentially to the patient’s physician.
According to Psynomics, doctors are constantly making diagnostic and treatment decisions based on limited and imperfect information. The tests are designed to provide objective data for use by doctors in combination with their other evaluations to arrive at a timely and accurate diagnosis of a patient’s condition and the right therapy.
A recent article in the magazine “Science”, reviewing the company and its science, announced that Psynomics was the first company to venture into the new field of psychiatric gene testing, the company says.
Psynome™ tests for two mutations of the GRK3 gene that have been associated with bipolar disorder in multiple studies of hundreds of patients and Psynome2™ tests for serotonin transporter (SSRI) response as a predictor of patient response to serotonin based drugs, the most commonly prescribed drug therapies in psychiatry today. Psynomics’ lab work is reproducible and performed in a CLIA and state regulated laboratory.
In addition to being the CSO of Psynomics and a professor of psychiatry at the University of California, San Diego, Dr. Kelsoe is also a practicing psychiatrist who sees and treats bipolar patients every week.
Some MRSA infections could be tackled using widely-available antibiotics, suggests new research. A team of scientists used genome sequencing technology to identify which genes make MRSA susceptible to a previously defined combination of drugs. They identified a number of mutations centered around a protein known as a penicillin-binding protein 2a or PBP2a.